All In Biotech

NDA 214755 · Alkermes INC

Lumryz

Sodium Oxybate · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 1, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

59

17 Phase 3, 4 recruiting

FAERS reports

5,012

1,731 serious, 123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE Central Nervous System Depression LUMRYZ (sodium oxybate) is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with LUMRYZ at recommended doses [see Warnings and Precautions (5.1) ] . Many patients who received sodium oxybate during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials (14) ] . Abuse and Misuse LUMRYZ (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2) ] . Because of the risks of CNS depression and abuse and misuse,...

What it is approved for

From the label in effect Sep 8, 2026.

LUMRYZ is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. LUMRYZ is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1 ).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • LUMRYZ · SODIUM OXYBATE 7.5GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
  • LUMRYZ · SODIUM OXYBATE 4.5GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
  • LUMRYZ · SODIUM OXYBATE 9GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
  • LUMRYZ · SODIUM OXYBATE 6GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxybate" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • somnolence896
  • insomnia872
  • middle insomnia807
  • nausea748
  • product dose omission issue645
  • fatigue612
  • drug ineffective567
  • initial insomnia454
  • dizziness405
  • anxiety401
  • intentional dose omission384
  • feeling abnormal377

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20082
20092
201027
201115
201212
20135
20145
201517
201616
201722
201852
201939
202019
202128
202228
2023551
20242,469
20251,233
2026467

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lumryz (Sodium Oxybate)

2024 spending

$16.1M

Beneficiaries

233

1,219 claims

Per beneficiary

$69,247

$492.99 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$2,175,379
2024$16,134,521

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 127 on PubMed

Sponsor: Alkermes INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.